Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
January 08, 2025 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
December 19, 2024 08:00 ET
|
Alumis Inc.
In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers
December 04, 2024 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Neurology Clinical Trials Market Size Is Expected To Reach a Revenue Of USD 9,231.1 Mn By 2033, at 5.8% CAGR: Dimension Market Research
November 25, 2024 09:26 ET
|
Dimension Market Research
New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Market Overview The Global Neurology Clinical Trials Market size is expected to reach USD 5,549.3 million by 2024 and it is further anticipated to reach...
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
November 01, 2024 13:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
September 26, 2024 01:00 ET
|
PolTREG S.A.
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy...
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
September 19, 2024 10:50 ET
|
Precede Biosciences, Inc.
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
September 16, 2024 01:00 ET
|
PolTREG S.A.
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to...
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
August 22, 2024 07:00 ET
|
Abata
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
Multiple Sclerosis Market Set to Reach USD 33.57 Billion by 2032, Growing at a CAGR of 5.4% | Polaris Market Research (PMR)
August 19, 2024 08:25 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Market Overview: The multiple sclerosis market was estimated at USD 21.04 billion in 2023. The market valuation is expected to be USD 33.57 billion...